{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:32:16Z","timestamp":1791235936101,"version":"4.1.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,5,15]],"date-time":"2013-05-15T00:00:00Z","timestamp":1368576000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s11060-013-1151-1","type":"journal-article","created":{"date-parts":[[2013,5,14]],"date-time":"2013-05-14T16:46:40Z","timestamp":1368550000000},"page":"1-11","source":"Crossref","is-referenced-by-count":27,"title":["New avenues in the medical treatment of Cushing\u2019s disease: corticotroph tumor targeted therapy"],"prefix":"10.1007","volume":"114","author":[{"given":"Maria","family":"Fleseriu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Petersenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,15]]},"reference":[{"key":"1151_CR1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2265.1994.tb02486.x","volume":"40","author":"J Etxabe","year":"1994","unstructured":"Etxabe J, Vazquez JA (1994) Morbidity and mortality in Cushing\u2019s disease: an epidemiological approach. Clin Endocrinol (Oxf) 40:479\u2013484","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1151_CR2","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","volume":"367","author":"J Newell-Price","year":"2006","unstructured":"Newell-Price J, Bertagna X, Grossman AB, Nieman LK (2006) Cushing\u2019s syndrome. Lancet 367:1605\u20131617. doi: 10.1016\/S0140-6736(06)68699-6","journal-title":"Lancet"},{"issue":"Suppl 1","key":"1151_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000314297","volume":"92","author":"C Steffensen","year":"2010","unstructured":"Steffensen C, Bak AM, Rubeck KZ, Jorgensen JO (2010) Epidemiology of Cushing\u2019s syndrome. Neuroendocrinology 92(Suppl 1):1\u20135. doi: 10.1159\/000314297","journal-title":"Neuroendocrinology"},{"key":"1151_CR4","volume-title":"Williams textbook of endocrinology","author":"S Melmed","year":"2011","unstructured":"Melmed S, Kleinberg D, Ho K (2011) Pituitary physiology and diagnostic evaluation. In: Melmed S, Polonsky K, Larsen P, Kronenberg H (eds) Williams textbook of endocrinology, 12th edn. Elsevier, Philadelphia","edition":"12"},{"key":"1151_CR5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1210\/jcem-40-4-675","volume":"40","author":"DT Krieger","year":"1975","unstructured":"Krieger DT, Allen W (1975) Relationship of bioassayable and immunoassayable plasma ACTH and cortisol concentrations in normal subjects and in patients with Cushing\u2019s disease. J Clin Endocrinol Metab 40:675\u2013687","journal-title":"J Clin Endocrinol Metab"},{"key":"1151_CR6","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1210\/jcem-64-5-1027","volume":"64","author":"JH Liu","year":"1987","unstructured":"Liu JH, Kazer RR, Rasmussen DD (1987) Characterization of the twenty-four hour secretion patterns of adrenocorticotropin and cortisol in normal women and patients with Cushing\u2019s disease. J Clin Endocrinol Metab 64:1027\u20131035","journal-title":"J Clin Endocrinol Metab"},{"key":"1151_CR7","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/jc.83.2.688","volume":"83","author":"F Roelfsema","year":"1998","unstructured":"Roelfsema F, Pincus SM, Veldhuis JD (1998) Patients with Cushing\u2019s disease secrete adrenocorticotropin and cortisol jointly more asynchronously than healthy subjects. J Clin Endocrinol Metab 83:688\u2013692","journal-title":"J Clin Endocrinol Metab"},{"key":"1151_CR8","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1210\/jcem-48-5-760","volume":"48","author":"RM Boyar","year":"1979","unstructured":"Boyar RM, Witkin M, Carruth A, Ramsey J (1979) Circadian cortisol secretory rhythms in Cushing\u2019s disease. J Clin Endocrinol Metab 48:760\u2013765","journal-title":"J Clin Endocrinol Metab"},{"key":"1151_CR9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1530\/acta.0.1120230","volume":"112","author":"J Tourniaire","year":"1986","unstructured":"Tourniaire J, Chalendar D, Rebattu B, Fevre-Montange M, Bajard L, Mazenod B, Dechaud H, Abou Samra AB, van Cauter E (1986) The 24-h cortisol secretory pattern in Cushing\u2019s syndrome. Acta Endocrinol (Copenh) 112:230\u2013237","journal-title":"Acta Endocrinol (Copenh)"},{"key":"1151_CR10","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1530\/eje.0.1360394","volume":"136","author":"G Berg van den","year":"1997","unstructured":"van den Berg G, Pincus SM, Veldhuis JD, Frolich M, Roelfsema F (1997) Greater disorderliness of ACTH and cortisol release accompanies pituitary-dependent Cushing\u2019s disease. Eur J Endocrinol 136:394\u2013400","journal-title":"Eur J Endocrinol"},{"key":"1151_CR11","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","volume":"93","author":"BM Biller","year":"2008","unstructured":"Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing\u2019s syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454\u20132462. doi: 10.1210\/jc.2007-2734","journal-title":"J Clin Endocrinol Metab"},{"key":"1151_CR12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2265.2005.02380.x","volume":"63","author":"AB Atkinson","year":"2005","unstructured":"Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B (2005) Long-term remission rates after pituitary surgery for Cushing\u2019s disease: the need for long-term surveillance. Clin Endocrinol (Oxf) 63:549\u2013559. doi: 10.1111\/j.1365-2265.2005.02380.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1151_CR13","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1210\/jc.2007-2013","volume":"93","author":"CG Patil","year":"2008","unstructured":"Patil CG, Prevedello DM, Lad SP, Vance ML, Thorner MO, Katznelson L, Laws ER Jr (2008) Late recurrences of Cushing\u2019s disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 93:358\u2013362. doi: 10.1210\/jc.2007-2013","journal-title":"J Clin Endocrinol Metab"},{"key":"1151_CR14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","volume":"20","author":"YC Patel","year":"1999","unstructured":"Patel YC (1999) Somatostatin and its receptor family. Front Neuroendocrinol 20:157\u2013198. doi: 10.1006\/frne.1999.0183","journal-title":"Front Neuroendocrinol"},{"key":"1151_CR15","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1210\/en.133.6.2561","volume":"133","author":"JF Bruno","year":"1993","unstructured":"Bruno JF, Xu Y, Song J, Berelowitz M (1993) Tissue distribution of somatostatin receptor subtype messenger ribonucleic acid in the rat. Endocrinology 133:2561\u20132567","journal-title":"Endocrinology"},{"key":"1151_CR16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/002215540305100107","volume":"51","author":"AM O\u2019Carroll","year":"2003","unstructured":"O\u2019Carroll AM (2003) Localization of messenger ribonucleic acids for somatostatin receptor subtypes (sstr1\u20135) in the rat adrenal gland. J Histochem Cytochem 51:55\u201360","journal-title":"J Histochem Cytochem"},{"key":"1151_CR17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000079048","volume":"32","author":"LJ Hofland","year":"2004","unstructured":"Hofland LJ, Lamberts SW (2004) Somatostatin receptors in pituitary function, diagnosis and therapy. Front Horm Res 32:235\u2013252","journal-title":"Front Horm Res"},{"key":"1151_CR18","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1055\/s-0032-1314859","volume":"120","author":"N Unger","year":"2012","unstructured":"Unger N, Ueberberg B, Schulz S, Saeger W, Mann K, Petersenn S (2012) Differential expression of somatostatin receptor subtype 1\u20135 proteins in numerous human normal tissues. Exp Clin Endocrinol Diabetes 120:482\u2013489. doi: 10.1055\/s-0032-1314859","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"1151_CR19","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/eje.1.01876","volume":"152","author":"LJ Hofland","year":"2005","unstructured":"Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A, Lamberts SW (2005) The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152:645\u2013654. doi: 10.1530\/eje.1.01876","journal-title":"Eur J Endocrinol"},{"key":"1151_CR20","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1210\/jc.2006-1245","volume":"91","author":"DL Batista","year":"2006","unstructured":"Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA, Klibanski A (2006) The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 91:4482\u20134488. doi: 10.1210\/jc.2006-1245","journal-title":"J Clin Endocrinol Metab"},{"key":"1151_CR21","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/0024-3205(77)90084-4","volume":"21","author":"KH Voight","year":"1977","unstructured":"Voight KH, Fehm HL, Lang RE, Walter R (1977) The effect of somatostatin and of prolyl-leucyl-glycinamide (MIF) on ACTH release in dispersed pituitary cells. Life Sci 21:739\u2013745","journal-title":"Life Sci"},{"key":"1151_CR22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF01468882","volume":"54","author":"HL Fehm","year":"1976","unstructured":"Fehm HL, Voigt KH, Lang R, Beinert KE, Raptis S, Pfeiffer EF (1976) Somatostatin: a potent inhibitor of ACTH-hypersecretion in adrenal insufficiency. Klin Wochenschr 54:173\u2013175","journal-title":"Klin Wochenschr"},{"key":"1151_CR23","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1530\/acta.0.1200760","volume":"120","author":"SW Lamberts","year":"1989","unstructured":"Lamberts SW, Uitterlinden P, Klijn JM (1989) The effect of the long-acting somatostatin analogue SMS 201\u2013995 on ACTH secretion in Nelson\u2019s syndrome and Cushing\u2019s disease. Acta Endocrinol (Copenh) 120:760\u2013766","journal-title":"Acta Endocrinol (Copenh)"},{"key":"1151_CR24","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1210\/jcem-40-6-1125","volume":"40","author":"JB Tyrrell","year":"1975","unstructured":"Tyrrell JB, Lorenzi M, Gerich JE, Forsham PH (1975) Inhibition by somatostatin of ACTH secretion in Nelson\u2019s syndrome. J Clin Endocrinol Metab 40:1125\u20131127","journal-title":"J Clin Endocrinol Metab"},{"key":"1151_CR25","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1210\/endo-114-5-1546","volume":"114","author":"MR Brown","year":"1984","unstructured":"Brown MR, Rivier C, Vale W (1984) Central nervous system regulation of adrenocorticotropin secretion: role of somatostatins. Endocrinology 114:1546\u20131549","journal-title":"Endocrinology"},{"key":"1151_CR26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000124203","volume":"41","author":"J Kraicer","year":"1985","unstructured":"Kraicer J, Gajewski TC, Moor BC (1985) Release of pro-opiomelanocortin-derived peptides from the pars intermedia and pars distalis of the rat pituitary: effect of corticotrophin-releasing factor and somatostatin. Neuroendocrinology 41:363\u2013373","journal-title":"Neuroendocrinology"},{"key":"1151_CR27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF03349555","volume":"13","author":"B Ambrosi","year":"1990","unstructured":"Ambrosi B, Bochicchio D, Fadin C, Colombo P, Faglia G (1990) Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion. J Endocrinol Invest 13:257\u2013261","journal-title":"J Endocrinol Invest"},{"key":"1151_CR28","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/pgmj.72.849.403","volume":"72","author":"WW Herder de","year":"1996","unstructured":"de Herder WW, van der Lely AJ, Lamberts SW (1996) Somatostatin analogue treatment of neuroendocrine tumours. Postgrad Med J 72:403\u2013408","journal-title":"Postgrad Med J"},{"key":"1151_CR29","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2265.1990.tb00867.x","volume":"32","author":"C Invitti","year":"1990","unstructured":"Invitti C, de Martin M, Brunani A, Piolini M, Cavagnini F (1990) Treatment of Cushing\u2019s syndrome with the long-acting somatostatin analogue SMS 201\u2013995 (sandostatin). Clin Endocrinol (Oxf) 32:275\u2013281","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1151_CR30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/eje.0.1300125","volume":"130","author":"GK Stalla","year":"1994","unstructured":"Stalla GK, Brockmeier SJ, Renner U, Newton C, Buchfelder M, Stalla J, Muller OA (1994) Octreotide exerts different effects in vivo and in vitro in Cushing\u2019s disease. Eur J Endocrinol 130:125\u2013131","journal-title":"Eur J Endocrinol"},{"key":"1151_CR31","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.mce.2007.10.015","volume":"286","author":"LJ Hofland","year":"2008","unstructured":"Hofland LJ (2008) Somatostatin and somatostatin receptors in Cushing\u2019s disease. Mol Cell Endocrinol 286:199\u2013205. doi: 10.1016\/j.mce.2007.10.015","journal-title":"Mol Cell Endocrinol"},{"issue":"Suppl 1","key":"1151_CR32","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1530\/eje.1.02350","volume":"156","author":"J Hoek van der","year":"2007","unstructured":"van der Hoek J, Lamberts SW, Hofland LJ (2007) Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas. Eur J Endocrinol 156(Suppl 1):S45\u2013S51. doi: 10.1530\/eje.1.02350","journal-title":"Eur J Endocrinol"},{"key":"1151_CR33","doi-asserted-by":"crossref","first-page":"E278","DOI":"10.1152\/ajpendo.00004.2005","volume":"289","author":"J Hoek van der","year":"2005","unstructured":"van der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffter P, Hoyer D, Cervia D, Taylor JE, Culler MD, Lamberts SW, Hofland LJ (2005) Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab 289:E278\u2013E287. doi: 10.1152\/ajpendo.00004.2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1151_CR34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1530\/EJE-11-0737","volume":"166","author":"U Plockinger","year":"2012","unstructured":"Plockinger U, Hoffmann U, Geese M, Lupp A, Buchfelder M, Flitsch J, Vajkoczy P, Jakob W, Saeger W, Schulz S, Dohrmann C (2012) DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours. Eur J Endocrinol 166:223\u2013234. doi: 10.1530\/EJE-11-0737","journal-title":"Eur J Endocrinol"},{"key":"1151_CR35","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1210\/en.142.1.477","volume":"142","author":"M Afargan","year":"2001","unstructured":"Afargan M, Janson ET, Gelerman G, Rosenfeld R, Ziv O, Karpov O, Wolf A, Bracha M, Shohat D, Liapakis G, Gilon C, Hoffman A, Stephensky D, Oberg K (2001) Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin. Endocrinology 142:477\u2013486","journal-title":"Endocrinology"},{"key":"1151_CR36","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/annonc\/mdl105","volume":"17","author":"C Susini","year":"2006","unstructured":"Susini C, Buscail L (2006) Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 17:1733\u20131742. doi: 10.1093\/annonc\/mdl105","journal-title":"Ann Oncol"},{"key":"1151_CR37","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/nrd1255","volume":"2","author":"G Weckbecker","year":"2003","unstructured":"Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C (2003) Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2:999\u20131017. doi: 10.1038\/nrd1255","journal-title":"Nat Rev Drug Discov"},{"key":"1151_CR38","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","volume":"146","author":"C Bruns","year":"2002","unstructured":"Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707\u2013716","journal-title":"Eur J Endocrinol"},{"key":"1151_CR39","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1210\/jc.2008-0027","volume":"93","author":"RD Murray","year":"2008","unstructured":"Murray RD, Melmed S (2008) A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 93:2957\u20132968. doi: 10.1210\/jc.2008-0027","journal-title":"J Clin Endocrinol Metab"},{"key":"1151_CR40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1210\/jc.2008-1008","volume":"94","author":"M Boscaro","year":"2009","unstructured":"Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J (2009) Treatment of pituitary-dependent Cushing\u2019s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94:115\u2013122. doi: 10.1210\/jc.2008-1008","journal-title":"J Clin Endocrinol Metab"},{"key":"1151_CR41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000327429","volume":"94","author":"V Castillo","year":"2011","unstructured":"Castillo V, Theodoropoulou M, Stalla J, Gallelli MF, Cabrera-Blatter MF, Haedo MR, Labeur M, Schmid HA, Stalla GK, Arzt E (2011) Effect of SOM230 (pasireotide) on corticotropic cells: action in dogs with Cushing\u2019s disease. Neuroendocrinology 94:124\u2013136. doi: 10.1159\/000327429","journal-title":"Neuroendocrinology"},{"key":"1151_CR42","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1530\/eje.1.01998","volume":"153","author":"AP Silva","year":"2005","unstructured":"Silva AP, Schoeffter P, Weckbecker G, Bruns C, Schmid HA (2005) Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. Eur J Endocrinol 153:R7\u2013R10. doi: 10.1530\/eje.1.01998","journal-title":"Eur J Endocrinol"},{"key":"1151_CR43","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM (2012) A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med 366:914\u2013924. doi: 10.1056\/NEJMoa1105743","journal-title":"N Engl J Med"},{"key":"1151_CR44","doi-asserted-by":"crossref","first-page":"P3","DOI":"10.1210\/er.2009-0043","volume":"32","author":"R Henry","year":"2011","unstructured":"Henry R, Mudaliar S, Hermosillo Res\u00e9ndiz K, Ligueros-Saylan M, Chenji S, Golor G (2011) Mechanism and management of hyperglycemia associated with pasireotide: results from studies in healthy volunteers. Endocr Rev 32:P3\u2013P274","journal-title":"Endocr Rev"},{"key":"1151_CR45","author":"Y Reznik","year":"2012","unstructured":"Reznik Y, Bertherat J, Borson-Chazot F, Brue T, Chanson P, Cortet-Rudelli C, Delemer B, Tabarin A, Bisot-Locard S, Verges B (2012) Management of hyperglycaemia in Cushing\u2019s disease: experts\u2019 proposals on the use of pasireotide. Diabetes Metab. doi: 10.1016\/j.diabet.2012.10.005","journal-title":"Diabetes Metab"},{"key":"1151_CR46","unstructured":"Novartis (2012) Signifor full US prescribing information. http:\/\/www.pharma.us.novartis.com\/cs\/www.pharma.us.novartis.com\/product\/pi\/pdf\/signifor.pdf . Accessed 21 Feb 2013"},{"key":"1151_CR47","unstructured":"Novartis (2012) Signifor EU SPC. http:\/\/www.signifor.com\/european-product-characteristics.jsp . Accessed 21 Feb 2013"},{"key":"1151_CR48","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1210\/jc.2003-030837","volume":"89","author":"R Pivonello","year":"2004","unstructured":"Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SW (2004) Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89:2452\u20132462","journal-title":"J Clin Endocrinol Metab"},{"key":"1151_CR49","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1385\/ENDO:14:3:329","volume":"14","author":"L Stefaneanu","year":"2001","unstructured":"Stefaneanu L, Kovacs K, Horvath E, Buchfelder M, Fahlbusch R, Lancranjan L (2001) Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine 14:329\u2013336","journal-title":"Endocrine"},{"key":"1151_CR50","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11154-008-9082-4","volume":"10","author":"C Bruin de","year":"2009","unstructured":"de Bruin C, Feelders RA, Lamberts SW, Hofland LJ (2009) Somatostatin and dopamine receptors as targets for medical treatment of Cushing\u2019s syndrome. Rev Endocr Metab Disord 10:91\u2013102. doi: 10.1007\/s11154-008-9082-4","journal-title":"Rev Endocr Metab Disord"},{"key":"1151_CR51","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1517\/14656566.1.3.555","volume":"1","author":"A Colao","year":"2000","unstructured":"Colao A, Lombardi G, Annunziato L (2000) Cabergoline. Expert Opin Pharmacother 1:555\u2013574. doi: 10.1517\/14656566.1.3.555","journal-title":"Expert Opin Pharmacother"},{"key":"1151_CR52","doi-asserted-by":"crossref","first-page":"968","DOI":"10.4158\/EP10031.OR","volume":"16","author":"AR Lila","year":"2010","unstructured":"Lila AR, Gopal RA, Acharya SV, George J, Sarathi V, Bandgar T, Menon PS, Shah NS (2010) Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy. Endocr Pract 16:968\u2013976. doi: 10.4158\/ep10031.or","journal-title":"Endocr Pract"},{"key":"1151_CR53","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1210\/jc.2008-1533","volume":"94","author":"R Pivonello","year":"2009","unstructured":"Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G, Hofland LJ, Lamberts SW, Colao A (2009) The medical treatment of Cushing\u2019s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94:223\u2013230. doi: 10.1210\/jc.2008-1533","journal-title":"J Clin Endocrinol Metab"},{"key":"1151_CR54","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1530\/EJE-10-0382","volume":"163","author":"A Godbout","year":"2010","unstructured":"Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A (2010) Cabergoline monotherapy in the long-term treatment of Cushing\u2019s disease. Eur J Endocrinol 163:709\u2013716. doi: 10.1530\/EJE-10-0382","journal-title":"Eur J Endocrinol"},{"key":"1151_CR55","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1365-2796.2007.01874.x","volume":"263","author":"VG Rasmussen","year":"2008","unstructured":"Rasmussen VG, Poulsen SH, Dupont E, Ostergaard K, Safikhany G, Egeblad H (2008) Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson\u2019s disease. J Intern Med 263:90\u201398. doi: 10.1111\/j.1365-2796.2007.01874.x","journal-title":"J Intern Med"},{"key":"1151_CR56","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","volume":"356","author":"R Schade","year":"2007","unstructured":"Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29\u201338. doi: 10.1056\/NEJMoa062222","journal-title":"N Engl J Med"},{"key":"1151_CR57","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/mds.21639","volume":"22","author":"G Simonis","year":"2007","unstructured":"Simonis G, Fuhrmann JT, Strasser RH (2007) Meta-analysis of heart valve abnormalities in Parkinson\u2019s disease patients treated with dopamine agonists. Mov Disord 22:1936\u20131942. doi: 10.1002\/mds.21639","journal-title":"Mov Disord"},{"key":"1151_CR58","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1210\/jc.2007-2658","volume":"93","author":"M Kars","year":"2008","unstructured":"Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ, Pereira AM (2008) Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8\u00a0years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 93:3348\u20133356. doi: 10.1210\/jc.2007-2658","journal-title":"J Clin Endocrinol Metab"},{"key":"1151_CR59","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1210\/jc.2012-2328","volume":"97","author":"F Pecori Giraldi","year":"2012","unstructured":"Pecori Giraldi F, Ambrogio AG, Andrioli M, Sanguin F, Karamouzis I, Corsello SM, Scaroni C, Arvat E, Pontercorvi A, Cavagnini F (2012) Potential role for retinoic acid in patients with Cushing\u2019s disease. J Clin Endocrinol Metab 97:3577\u20133583. doi: 10.1210\/jc.2012-2328","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"1151_CR60","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1530\/eje.1.02348","volume":"156","author":"A Colao","year":"2007","unstructured":"Colao A, Filippella M, Pivonello R, Di Somma C, Faggiano A, Lombardi G (2007) Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours. Eur J Endocrinol 156(Suppl 1):S57\u2013S63. doi: 10.1530\/eje.1.02348","journal-title":"Eur J Endocrinol"},{"key":"1151_CR61","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMc1000094","volume":"362","author":"RA Feelders","year":"2010","unstructured":"Feelders RA, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, van Heerebeek R, de Jong FH, van der Lely AJ, de Herder WW, Hofland LJ, Lamberts SW (2010) Pasireotide alone or with cabergoline and ketoconazole in Cushing\u2019s disease. N Engl J Med 362:1846\u20131848. doi: 10.1056\/NEJMc1000094","journal-title":"N Engl J Med"},{"key":"1151_CR62","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11102-010-0264-1","volume":"14","author":"TH Dillard","year":"2011","unstructured":"Dillard TH, Gultekin SH, Delashaw JB Jr, Yedinak CG, Neuwelt EA, Fleseriu M (2011) Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. Pituitary 14:80\u201391. doi: 10.1007\/s11102-010-0264-1","journal-title":"Pituitary"},{"issue":"Suppl 1","key":"1151_CR63","doi-asserted-by":"crossref","first-page":"119","DOI":"10.6061\/clinics\/2012(Sup01)20","volume":"67","author":"LD Ortiz","year":"2012","unstructured":"Ortiz LD, Syro LV, Scheithauer BW, Rotondo F, Uribe H, Fadul CE, Horvath E, Kovacs K (2012) Temozolomide in aggressive pituitary adenomas and carcinomas. Clinics (Sao Paulo) 67(Suppl 1):119\u2013123","journal-title":"Clinics (Sao Paulo)"},{"key":"1151_CR64","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1055\/s-0030-1253419","volume":"118","author":"H Bode","year":"2010","unstructured":"Bode H, Seiz M, Lammert A, Brockmann MA, Back W, Hammes HP, Thome C (2010) SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Exp Clin Endocrinol Diabetes 118:760\u2013763. doi: 10.1055\/s-0030-1253419","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"1151_CR65","doi-asserted-by":"crossref","first-page":"E280","DOI":"10.1210\/jc.2010-0441","volume":"95","author":"ZM Bush","year":"2010","unstructured":"Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA Jr, Vance ML, Thorner MO, Laws ER Jr, Lopes MB (2010) Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 95:E280\u2013E290. doi: 10.1210\/jc.2010-0441","journal-title":"J Clin Endocrinol Metab"},{"key":"1151_CR66","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1530\/EJE-10-0629","volume":"163","author":"M Losa","year":"2010","unstructured":"Losa M, Mazza E, Terreni MR, McCormack A, Gill AJ, Motta M, Cangi MG, Talarico A, Mortini P, Reni M (2010) Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol 163:843\u2013851. doi: 10.1530\/EJE-10-0629","journal-title":"Eur J Endocrinol"},{"key":"1151_CR67","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1210\/jc.2010-0644","volume":"95","author":"G Raverot","year":"2010","unstructured":"Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, Francois P, Jouanneau E, Passagia JG, Bernier M, Cornelius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T (2010) Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95:4592\u20134599. doi: 10.1210\/jc.2010-0644","journal-title":"J Clin Endocrinol Metab"},{"key":"1151_CR68","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00401-007-0279-5","volume":"115","author":"K Kovacs","year":"2008","unstructured":"Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, Ortiz LD, Penagos LC (2008) MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol (Berl) 115:261\u2013262. doi: 10.1007\/s00401-007-0279-5","journal-title":"Acta Neuropathol (Berl)"},{"key":"1151_CR69","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1172\/JCI11098","volume":"108","author":"M Paez-Pereda","year":"2001","unstructured":"Paez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, Uhl E, Losa M, Stalla J, Grubler Y, Missale C, Arzt E, Stalla GK (2001) Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 108:1123\u20131131. doi: 10.1172\/JCI11098","journal-title":"J Clin Invest"},{"key":"1151_CR70","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1210\/en.2005-0958","volume":"147","author":"D Giacomini","year":"2006","unstructured":"Giacomini D, Paez-Pereda M, Theodoropoulou M, Labeur M, Refojo D, Gerez J, Chervin A, Berner S, Losa M, Buchfelder M, Renner U, Stalla GK, Arzt E (2006) Bone morphogenetic protein-4 inhibits corticotroph tumor cells: involvement in the retinoic acid inhibitory action. Endocrinology 147:247\u2013256. doi: 10.1210\/en.2005-0958","journal-title":"Endocrinology"},{"key":"1151_CR71","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1210\/en.2006-0414","volume":"147","author":"V Castillo","year":"2006","unstructured":"Castillo V, Giacomini D, P\u00e1ez-Pereda M, Stalla J, Labeur M, Theodoropoulou M, Holsboer F, Grossman AB, Stalla GK, Arzt E (2006) Retinoic acid as a novel medical therapy for Cushing\u2019s disease in dogs. Endocrinology 147:4438\u20134444. doi: 10.1210\/en.2006-0414","journal-title":"Endocrinology"},{"key":"1151_CR72","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1172\/JCI60417","volume":"121","author":"H Fukuoka","year":"2011","unstructured":"Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren S-G, Bruyette D, Melmed S (2011) EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest 121:4712\u20134721. doi: 10.1172\/jci60417","journal-title":"J Clin Invest"},{"key":"1151_CR73","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1210\/me.2004-0471","volume":"19","author":"MA Fernando","year":"2005","unstructured":"Fernando MA, Heaney AP (2005) Alpha1-adrenergic receptor antagonists: novel therapy for pituitary adenomas. Mol Endocrinol 19:3085\u20133096. doi: 10.1210\/me.2004-0471","journal-title":"Mol Endocrinol"},{"key":"1151_CR74","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","volume":"97","author":"M Fleseriu","year":"2012","unstructured":"Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C (2012) Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome. J Clin Endocrinol Metab 97:2039\u20132049. doi: 10.1210\/jc.2011-3350","journal-title":"J Clin Endocrinol Metab"},{"key":"1151_CR75","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2004-835369","volume":"4","author":"SH Uum van","year":"2004","unstructured":"van Uum SH, Lenders JW, Hermus AR (2004) Cortisol, 11beta-hydroxysteroid dehydrogenases, and hypertension. Semin Vasc Med 4:121\u2013128. doi: 10.1055\/s-2004-835369","journal-title":"Semin Vasc Med"},{"key":"1151_CR76","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1530\/EJE-09-0098","volume":"160","author":"F Castinetti","year":"2009","unstructured":"Castinetti F, Fassnacht M, Johanssen S, Terzolo M, Bouchard P, Chanson P, Do Cao C, Morange I, Pico A, Ouzounian S, Young J, Hahner S, Brue T, Allolio B, Conte-Devolx B (2009) Merits and pitfalls of mifepristone in Cushing\u2019s syndrome. Eur J Endocrinol 160:1003\u20131010. doi: 10.1530\/EJE-09-0098","journal-title":"Eur J Endocrinol"},{"key":"1151_CR77","first-page":"171","volume":"13","author":"NA Tritos","year":"2012","unstructured":"Tritos NA, Biller BM (2012) Advances in medical therapies for Cushing\u2019s syndrome. Discov Med 13:171\u2013179","journal-title":"Discov Med"},{"key":"1151_CR78","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0960-0760(94)90267-4","volume":"49","author":"D Engelhardt","year":"1994","unstructured":"Engelhardt D, Weber MM (1994) Therapy of Cushing\u2019s syndrome with steroid biosynthesis inhibitors. J Steroid Biochem Mol Biol 49:261\u2013267","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1151_CR79","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3109\/9781420021141-26","volume-title":"Drug-induced liver disease","author":"R Moseley","year":"2007","unstructured":"Moseley R (2007) Antibacterial and antifungal agents. In: Kaplowitz N, DeLeve L (eds) Drug-induced liver disease, 2nd edn. Informa Healthcare USA, New York, pp 527\u2013546","edition":"2"},{"key":"1151_CR80","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1472-6823-10-10","volume":"10","author":"BM Biller","year":"2010","unstructured":"Biller BM, Colao A, Petersenn S, Bonert VS, Boscaro M (2010) Prolactinomas, Cushing\u2019s disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocr Disord 10:10. doi: 10.1186\/1472-6823-10-10","journal-title":"BMC Endocr Disord"},{"key":"1151_CR81","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1530\/EJE-07-0514","volume":"158","author":"F Castinetti","year":"2008","unstructured":"Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T (2008) Ketoconazole revisited: a preoperative or postoperative treatment in Cushing\u2019s disease. Eur J Endocrinol 158:91\u201399. doi: 10.1530\/EJE-07-0514","journal-title":"Eur J Endocrinol"},{"key":"1151_CR82","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1530\/EJE-12-0358","volume":"167","author":"C Baudry","year":"2012","unstructured":"Baudry C, Coste J, Bou Khalil R, Silvera S, Guignat L, Guibourdenche J, Abbas H, Legmann P, Bertagna X, Bertherat J (2012) Efficiency and tolerance of mitotane in Cushing\u2019s disease in 76 patients from a single center. Eur J Endocrinol 167:473\u2013481. doi: 10.1530\/EJE-12-0358","journal-title":"Eur J Endocrinol"},{"key":"1151_CR83","unstructured":"Pivonello R, Fleseriu M, Guignat L, Zhang Y, Robinson P, Taylor A, Watson C, Maldonado M, Hamrahian AH, Boscaro M, Biller BM (2012) Patients with Cushing disease achieve normal urinary cortisol with LCI699, a potent 11\u03b2-hydroxylase inhibitor: preliminary results from a multicenter, proof-of-concept study. Endocr Rev 33:OR49-41"},{"key":"1151_CR84","unstructured":"ClinicalTrials.gov (2012) NCT NCT01331239. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01331239 . Accessed 21 Feb 2013"},{"key":"1151_CR85","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.nec.2012.06.012","volume":"23","author":"M Fleseriu","year":"2012","unstructured":"Fleseriu M (2012) Medical management of persistent and recurrent Cushing disease. Neurosurg Clin N Am 23:653\u2013668. doi: 10.1016\/j.nec.2012.06.012","journal-title":"Neurosurg Clin N Am"},{"key":"1151_CR86","doi-asserted-by":"crossref","unstructured":"Fleseriu M, Petersenn S (2012) Medical management of Cushing's disease: what is the future? Pituitary 15:330\u2013341. doi: 10.1007\/s11102-012-0397-5","DOI":"10.1007\/s11102-012-0397-5"},{"key":"1151_CR87","doi-asserted-by":"crossref","unstructured":"Petersenn S (2011) Medical management of Cushing\u2019s disease. In: Swearingen B, Biller B (eds) Endocrine updates: Cushing\u2019s disease, vol 31. Springer, New York, pp 167\u2013182","DOI":"10.1007\/978-1-4614-0011-0_12"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-013-1151-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-013-1151-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-013-1151-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T18:15:46Z","timestamp":1715364946000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-013-1151-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,15]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["1151"],"URL":"https:\/\/doi.org\/10.1007\/s11060-013-1151-1","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,15]]}}}